Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor control.

guest :: login DKFZ
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help

Home > Publications database > Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor control. > Access to Fulltext

Information
Files

Tobemstomig, a novel bispecific antibody, preferentially blocks PD-1 and LAG-3 on CD8 TILs to expand stem-like T-cells for sustained tumor control. - DKFZ-2026-01430

Main document file(s):

Similar records

DKFZ :: :: :: ::
Powered by v1.1.7 |
Maintained by

Impressum | Data Privacy Policy